Caroline Ram-Wolff

Caroline Ram-Wolff

Auto-generated profile, based on publicly available information

Caroline Ram-Wolff

Dermatologie, hôpital Saint-Louis, AP–HP, Paris, France

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
GDGabor Dobos
Gabor Dobos
Anne PohrtAnne Pohrt
Anne Pohrt
CRCaroline Ram-Wolff
Caroline Ram-Wolff
Céleste LebbéCéleste Lebbé
Céleste Lebbé
JBJean-David Bouaziz
Jean-David Bouaziz
AMAdèle De Masson
Adèle De Masson
Cutaneous T-cell lymphomas (CTCL) are a heterogenous group of rare diseases. Many studies have reported on local epidemiology or geographic clustering, however we lack information from a global perspective. A systematic review and meta-analysis was conducted in Medline and the Cochrane Library based on a previously registered protocol and according to the preferred reporting of items for systematic reviews and meta-analyses (PRISMA). We selected publications that enrolled at least 100 patients with primary cutaneous lymphomas according to the current classifications. The relative frequencies (proportions) of subtypes were compared between studies and geographic regions in a meta-analysis. In total, 26 studies met our inclusion criteria, reporting on altogether 16,953 patients. Within primary cutaneous lymphomas, CTCL appeared to be 15% more frequent in Asian populations. Mycosis fungoides (MF) accounted for 62% of CTCL, with an important heterogeneity in frequencies between studies and continents. The proportion of Sézary syndrome (SS) was 3%, stable worldwide. Rare CTCL, such as NK/T-cell lymphoma or subcutaneous panniculitis-like lymphoma, were more frequent in Asian studies. This global meta-analysis of CTCL confirmed the predominance of CTCL among primary cutaneous lymphomas (83% on average) in the three analyzed continents, most of which were MF cases. It revealed the same proportions of SS across continents, and the heterogeneity of MF frequencies, suggesting the possible role of environmental factors in the pathophysiology of the latter. Registration number: CRD42020148295 (PROSPERO).

8 June 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MDMaëlle Dumont
Maëlle Dumont
Maxime BattistellaMaxime Battistella
Maxime Battistella
CRCaroline Ram-Wolff
Caroline Ram-Wolff
MBMartine Bagot
Martine Bagot
AMAdèle De Masson
Adèle De Masson
Primary cutaneous B-cell lymphomas are rare entities that develop primarily in the skin. They constitute a heterogeneous group that represents around a quarter of primary cutaneous lymphomas. The 2018 update of the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification differentiates primary cutaneous marginal zone lymphoma and primary cutaneous follicle center lymphoma with an indolent course from primary cutaneous diffuse large B-cell lymphoma, leg type with an aggressive behavior. The broad spectrum of clinical presentations and the disease course marked by frequent relapses are diagnostic and therapeutic challenges. The classification of these diseases has been refined in recent years, which allows to better define their immunopathogenesis and specific management. In the present article, we review the main clinico-biological characteristics and the current therapeutic options of these three main subsets. Based on the recent therapeutic advances in nodal B-cell lymphomas, we focus on the development of novel treatment options applicable to primary cutaneous B-cell lymphomas, including targeted therapies, combination treatments and immunotherapeutic approaches, and cover basic, translational and clinical aspects aiming to improve the treatment of cutaneous B-cell lymphomas.

24 February 2022 in Blood
Verified
Journal Article
Open access
PDF file
JDJérémie Delaleu
Jérémie Delaleu
RKRathana Kim
Rathana Kim
LZLin-Pierre Zhao
Lin-Pierre Zhao
AMAdèle De Masson
Adèle De Masson
MVMarie-Dominique Vignon-Pennamen
Marie-Dominique Vignon-Pennamen
Maxime BattistellaMaxime Battistella
Maxime Battistella
Applying next-generation sequencing to paired skin and marrow biopsies, Delaleu et al describe an entity they term “myelodysplasia cutis,” comprising histologic features of histiocytoid Sweet syndrome in the skin and a clonally related myelodysplasia in the bone marrow. This can be distinguished from forms of histiocytoid Sweet syndrome not associated with myelodysplastic syndromes, as well as classical neutrophilic Sweet syndrome associated with various malignant and nonmalignant diseases and leukemia cutis where the infiltrating cells are myeloblasts.

3 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MDMaëlle Dumont
Maëlle Dumont
RLRégis Peffault de Latour
Régis Peffault de Latour
CRCaroline Ram-Wolff
Caroline Ram-Wolff
MBMartine Bagot
Martine Bagot
AMAdèle De Masson
Adèle De Masson
Cutaneous T-cell lymphomas (CTCLs) are non-Hodgkin lymphomas that develop primarily in the skin. They account for almost 80% of primary cutaneous lymphomas. Epidermotropic CTCLs (mycosis fungoides (MF) and Sézary syndrome (SS)) are the most common form of CTCL. The course of the disease ranges from an indolent clinical behavior in early-stage disease to an aggressive evolution in the advanced stages. Advanced-stage disease is defined by the presence of tumors, erythroderma, or significant blood, nodal or visceral involvement. Advanced-stage disease is characterized by frequent disease relapses, refractory disease, a severely impaired quality of life and reduced overall survival. In the last twenty-five years, allogeneic hematopoietic stem cell transplantation (HSCT) has led to prolonged remissions in advanced CTCL, presumably linked to a graft-versus-lymphoma effect and is thus emerging as a potential cure of the disease. However, the high post-transplant relapse rate and severe morbidity and mortality associated with graft-versus-host disease and infections are important issues. Allogeneic HSCT is thus mostly considered in young patients with no comorbidities and an aggressive, advanced-stage CTCL. Allogeneic HSCT gives the best results in patients with a pre-transplant complete remission of the lymphoma. For this reason, one of the challenges is to define the best time to consider allogeneic HSCT in the disease course. Early identification of patients at high risk for progression is important to identify candidates who may benefit from allogeneic HSCT before their disease becomes treatment-refractory. This review describes the role of allogeneic HSCT in CTCL, summarizes the published data and future perspectives in this area.

20 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
JHJustine Habault
Justine Habault
NTNicolas Thonnart
Nicolas Thonnart
CRCaroline Ram-Wolff
Caroline Ram-Wolff
MBMartine Bagot
Martine Bagot
Armand BensussanArmand Bensussan
Armand Bensussan
AMAnne Marie-Cardine
Anne Marie-Cardine
Sézary syndrome (SS) is an aggressive cutaneous T cell lymphoma with poor prognosis mainly characterized by the expansion of a tumor CD4+ T cell clone in both skin and blood. So far, the development of new therapeutic strategies has been hindered by a lack of reproducible in vivo models closely reflecting patients’ clinical features. We developed an SS murine model consisting of the intravenous injection of Sézary patients’ PBMC, together with a mixture of interleukins, in NOD-SCID-gamma mice. Thirty-four to fifty days after injection, mice showed skin disorders similar to that observed in patients, with the detection of epidermis thickening and dermal tumor T cell infiltrates. Although experimental variability was observed, Sézary cells could be tracked in the blood stream, confirming that our model could efficiently exhibit both skin and blood involvement. Using this model, we evaluated the therapeutic potential of RT39, a cell-penetrating peptide derived from the survival protein anti-apoptosis clone 11 (AAC-11), that we previously characterized as specifically inducing apoptosis of Sézary patients’ malignant clone ex vivo. Systemic administration of RT39 led to cutaneous tumor T cells depletion, demonstrating efficient malignant cells’ targeting and a favorable safety profile. These preclinical data confirmed that RT39 might be an innovative therapeutic tool for Sézary syndrome.

4 December 2024 in Histopathology
Verified
Journal Article
Open access
FBFanny Beltzung
Fanny Beltzung
Marie BEYLOT-BARRYMarie BEYLOT-BARRY
Marie BEYLOT-BARRY
Maxime BattistellaMaxime Battistella
Maxime Battistella
CRCaroline Ram‐Wolff
Caroline Ram‐Wolff
AMAdèle De Masson
Adèle De Masson
BVBéatrice Vergier
Béatrice Vergier
Aims: Primary cutaneous marginal zone lymphoma (PCMZL) is considered a lymphoproliferative disorder (International Consensus Classification, ICC) or an overt lymphoma (WHO‐HAEM5). Seeking evidence for a reactive process or true lymphoma, we retrieved recurrent PCMZLs from the French Study Group of Cutaneous Lymphoma (GFELC) database.Methods: Histology, phenotype (light‐chain restriction, immunoglobulin, and immune‐receptor translocation‐associated protein‐1 [IRTA1] expression) and B‐cell clonality at diagnosis and recurrence were compared according to recurrence site (local, locoregional, or distant) and outcomes.Results: Initial lesions of the 61 patients (mean age 52) were mostly isolated on the trunk (48%) and classified T1 (70%). Times to first recurrence for local, locoregional, and distant recurrences, were 20, 29, and 37 months, respectively. Light‐chain restriction type did not differ significantly between local/locoregional recurrences and distal recurrences (P = 0.06; n = 60). The same B‐cell clones were identified for 23/42 local/locoregional recurrences, while 5/19 distant recurrences showed different clonal profiles (P = 0.0003). No tumour expressed IRTA1. Fifty‐eight tumours were heavy‐chain (IgG/IgG4) class‐switched PCMZLs and 3 IgM+/IgD– PCMZLs. All IgM+ tumours underwent either transformation (skin or brain) into diffuse large B‐cell lymphomas (DLBCLs) and extracutaneous spreading.Conclusion: As suggested by WHO‐HAEM5, immunoglobulin phenotype assessment (IgM alongside IgD) appears to be a possible valuable tool in the initial diagnosis of PCMZL to differentiate between the indolent class‐switched PCMZL (IgM‐negative) and IgM+ (IgD–) PCMZL, which has an uncertain prognosis. The variation in B‐cell rearrangements and light chain restriction observed in distant recurrences of PCMZL may suggest different antigen‐driven stimulation processes.